Loxicodegol

From WikiMD's Wellness Encyclopedia

Loxicodegol (also known as NKTR-181) is a novel opioid analgesic that was developed by Nektar Therapeutics for the management of chronic pain. It is a mu-opioid receptor agonist that is structurally related to oxycodone.

Pharmacology[edit | edit source]

Loxicodegol is a full agonist at the mu-opioid receptor. It is designed to have a slow rate of entry into the brain to reduce the euphoria and addiction potential associated with rapid-onset opioids.

Development and Approval[edit | edit source]

Loxicodegol was developed by Nektar Therapeutics. In March 2019, the U.S. Food and Drug Administration (FDA) did not approve the New Drug Application (NDA) for loxicodegol. The FDA stated that it was unable to approve the NDA in its present form and provided recommendations for additional data needed for approval.

Clinical Trials[edit | edit source]

Loxicodegol has undergone Phase 3 clinical trials for the management of chronic low back pain in opioid-naive patients. The results of the trials showed that loxicodegol was associated with less drug liking and less withdrawal than oxycodone.

See Also[edit | edit source]

Loxicodegol Resources
Wikipedia
WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD